A depletion assay using each anti-HSP antibody showed that, although HSP70, HSP90, and gp96 were all shown to bind melanoma antigen peptides such as a TRP-2-derived peptide, HSP70 was shown to be largely responsible for the anti-melanoma immunity. The gene discussed is HSP90B1; the disease is melanoma.